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http://dxObjectives: Shock waves have been shown to induce recruitment of intravenously injected endothelial progen-
itor cells to ischemic hind limbs in rats.We hypothesized that shock wave treatment as sole therapy would induce
angiogenesis in this ischemiamodel andwould lead tomobilization of endogenous endothelial (progenitor) cells.
Methods: A total of 18 rats, aged 5 weeks old, were subdivided into 3 groups: sham (n ¼ 6), ischemic muscle
with shock wave treatment (shock wave treatment group, n ¼ 6), and without shock wave treatment (control,
n ¼ 6). Hind limb ischemia was induced by ligation of the femoral artery. Three weeks later, shock wave treat-
ment (300 impulses at 0.1 mJ/mm2) was applied to the adductor muscle; the controls were left untreated. Muscle
samples were analyzed using real-time polymerase chain reaction for angiogenic factors and chemoattractants
for endothelial progenitor cell mobilization. Fluorescence activated cell sorting analysis of the peripheral blood
was performed for CD31/CD34-positive cells. Perfusion was measured using laser Doppler imaging. Functional
improvement was evaluated by walking analysis.
Results:Angiogenic factors/endothelial progenitor cell chemoattractants, stromal cell-derived factor-1 and vas-
cular endothelial growth factor, were increased in the treatment group, as shown by real-time polymerase chain
reaction, indicating the mobilization of endothelial progenitor cells. Fluorescence activated cell sorting analysis
of the peripheral blood revealed high numbers of CD31/CD34-positive cells in the treatment group. Greater
numbers of capillaries were found in the treated muscles. Blood perfusion increased markedly in the treatment
group and led to functional restoration, as shown by the results from the walking analysis.
Conclusions: Shockwave therapy therefore could develop into a feasible alternative to stem cell therapy in regen-
erative medicine, in particular for ischemic heart and limb disease. (J Thorac Cardiovasc Surg 2013;146:971-8)Shock wave therapy (SWT) causes relief of angina symp-
toms in patients with ischemic heart disease.1 Our group
has shown that direct epicardial application of shock waves
improves left ventricular function in chronic myocardial is-
chemia in rats. A significantly greater number of vessels and
endothelial cells were found in the ischemic myocardium.2
Clear evidence is available of neovascularization after
SWT.3,4 However, the origin of endothelial cells forming
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The Journal of Thoracic and Caangiogenesis owing to the sprouting of existing vessels or
by vasculogenesis with the recruitment of endogenous
endothelial progenitor cells (EPCs) and subsequent new
vessel formation has not been demonstrated.
Aicher and colleagues5 found enhanced recruitment of
intravenously injected EPCs to shock wave-treated ische-
mic hind limbs in rats. Stromal cell-derived factor-1
(SDF-1), the main chemoattractant for the recruitment
and homing of EPCs, was significantly upregulated in the
treated muscle. Shock waves were applied 24 hours before
cell injection as a preconditioning of the ischemic tissue.
These results were confirmed by Yeh and colleagues.6
We therefore hypothesized that SWT stimulates angio-
genesis and mobilizes endogenous EPCs without the neces-





The experiments were approved by the institutional animal care and use
committee at Chang Gung Memorial Hospital. The investigation
conformed to the ‘‘Guide for the Care and Use of Laboratory Animals’’
published by the US National Institutes of Health (NIH Publication No.
85-23, revised 1996; available from: www.nap.edu/catalog/5140.html).rdiovascular Surgery c Volume 146, Number 4 971
Abbreviations and Acronyms
Ct ¼ cycle threshold
CTR ¼ control
EPC ¼ endothelial progenitor cell
HIF-1a ¼ hypoxia-inducible factor 1a
PCNA ¼ proliferating cell nuclear antigen
SDF-1 ¼ stromal cell-derived factor-1
SWT ¼ shock wave therapy
VEGF ¼ vascular endothelial growth factor




SAtotal of 54, random,5- to6-week-oldSprague-Dawley rats (weight, 150-
190 g) were obtained from Charles River Technology (BioLASCO Taiwan,
Taipei, Taiwan). During the experiments, the ratswere housed under standard
conditions with a 12-hour light/dark cycle. Water and a commercial rat diet
were available ad libitum. The rats were randomly divided into 3 groups:
the control group (CTR, n¼ 18, hind limb ischemiawithout treatment), treat-
ment group (SWT, n¼ 18, hind limb ischemia with SWT), and sham group
(n¼ 18, sham surgery only). Next, 6 rats per group were anesthetized at 24
hours, 1 week, and 6 weeks after SWT. The whole adductor muscle was har-
vested and split in half into a proximal and distal portion.Of the distal portion,
the middle part around the former femoral artery was used for analysis to
avoid sampling variances of regions with greater or lesser ischemia.
A rat model of unilateral hind limb ischemia was performed in the treat-
ment and control groups, as described previously.5 In brief, anesthesia was
administered by an intraperitoneal injection of ketamine (Pfizer, NewYork,
NY; 100 mg/kg) and xylazine (Rompun, Bayer, Germany; 10 mg/kg). The
proximal portion of the left femoral artery, including the superficial and
deep branch, and the distal portion were occluded by a suture ligation. In
the sham group, the adductor muscle was surgically exposed exactly as
in the treatment and control rats. The sample size of each group at each
measurement point was 6.
Shock Wave Treatment
At 3 weeks after hind limb ischemia surgery, a single SWT was per-
formed in the treatment group (SWT); the CTR group was left untreated.
Anesthesia was given as described. The commercially available derma-
PACE device (Sanuwave Health, Alpharetta, Ga) and an Orthogold device
with applicator CG050-P (Tissue Regeneration Technologies, Woodstock,
Ga) were both used for SWT, delivering exactly the same treatment param-
eters. Both devices have been certified for human use. The following treat-
ment parameters were derived from our experience in human application
and could therefore be directly translated to the clinic. Thus, 300 impulses,
at an energy flux density of 0.1 mJ/mm2 and a frequency of 4 Hz, were ap-
plied to skin at the area of the adductor muscle, translating to 4 impulses/s
and less than 1.5 minutes overall treatment time. Common ultrasound gel
was used for coupling the shock wave applicators.
Real-Time Polymerase Chain Reaction
Real-time polymerase chain reaction analysis was performed 24 hours
and 6 weeks after treatment. One microgram of total RNA in muscle tissue
extracted using QIAzol reagent (Qiagene, Valencia, Calif) was reverse
transcribed. Complementary DNA equivalent 20 ng total RNAwas mixed
with 2X iQ SYBR Green Supermix and specific primers and then polymer-
ase chain reaction amplified by an iCycler iQ real-time polymerase chain
reaction detection system (Bio-Rad Laboratories, Hercules, Calif). The
following primer oligonucleotide sequences were used: b-actin, forward:
50-TTG CTG ACA GGA TGC AGA AGG AGA-30; reverse: 50-ACT
CCT GCT TGC TGATCC ACATCT-30); vascular endothelial growth fac-
tor (VEGF)-A (forward: 50-GCC CAT GAA GTG GTG AAG TT-30;972 The Journal of Thoracic and Cardiovascular Surgreverse: 50-ACT CCA GGG CTT CAT CAT TG-30); hypoxia-inducible
factor-1a (HIF-1a) (forward: 50-GGC GGC GAG AAC GAG AAG-30;
reverse: 50-GTG GCA ACT GAT GAG CAA GC-30); SDF-1 forward:
(50-ATT CTT TGA GAG CCATGT CGC CAG-30; reverse: 50-TCATGG
AAT TGA GTG CAT GCT GCG-30) and C-X-C chemokine receptor
type 4 (forward: 50-TCGTGCACAAGTGGATCTCCATCA-30; reverse:
50-TCATGGAAT TGAGTG CAT GCT GCG-30). The real-time polymer-
ase chain reaction amplicons were sequenced (Center of Molecular Medi-
cine, National Cheng Kong University, Taipei, Taiwan) and matched using
the National Center Biotechnology Information Basic Local Alignment
Search tool. The values of cycle threshold (Ct) were computed at the begin-
ning of logarithmic amplification of the reaction. The relative abundance of
each gene, normalized to the housekeeping gene b-actin, was calculated as
2DCt, where DCt ¼ Cttarget gene  Ctb-actin.
VEGF Enzyme-Linked Immunosorbent Assay
Muscle proteins were extracted by sonication in 500 mL phosphate-
buffered saline buffer. The VEGF concentrations were determined using
a mouse VEGF enzyme-linked immunosorbent assay kit according to the
protocol of the manufacturer (R&D Systems Europe, Abingdon, United
Kingdom). In brief, 50 mL of assay diluents RD1N were added to each
well of 96-well polystyrene microplates. Next, 50 mL of the standard, con-
trol, or samples were added to each well, mixed by gently tapping the plate
frame for 1 minute and incubated for 2 hours at room temperature. There-
after, washing with wash buffer (400 mL) was performed 5 times followed
by addition of 100 mL of mouse VEGF conjugate to each well, incubation
for 2 hours at room temperature, and washing again with wash buffer
5 times. Subsequently, 100 mL of substrate solution was added to each
well and incubated for 30 minutes at room temperature. Finally, 100 mL
of stop solution was added to each well, and the concentration was deter-
mined with an enzyme-linked immunosorbent assay reader at 450 nm.
The VEGF protein concentration is given as pg/mg protein (as determined
using the bicinchoninic acid method).
Immunohistochemistry
Muscle tissuewas taken from theadductormuscle at 24hours and6weeks
after treatment. The specimens were fixed in 3% phosphate-buffered saline-
buffered formaldehyde and embedded in paraffin, cut longitudinally into
4-mm sections, and transferred to polylysine-coated slides. Serial sections
were stained with hematoxylin and eosin, polyclonal anti-CD31 antibody
(Abbiotec, SanDiego,Calif), and amonoclonal antiproliferating cell nuclear
antigen (PCNA) antibody (Millipore,Billerica,Mass). In brief, thedeparaffi-
nized sections were preincubated with 3% hydrogen peroxide and horse se-
rum (Bio SB, Santa Barbara, Calif) to block endogenous peroxidase and
antigen activity before incubation with the primary antibody (CD31, 1:50
dilution; PCNA 1:250 dilution). PolyDetector horseradish peroxidase-
30-,30-diaminobenzidine detection system (Bio SB) was used to detect posi-
tive staining. The distal half of the adductor muscle was divided into 3 parts,
and 5 images from a section of each part were analyzed using a Zeiss Axio-
skop 2 plus microscope (Carl Zeiss, Munich, Germany). All images of each
specimen were captured using a Cool charge-coupled device camera
(SNAP-Pro cf Digital Kit; Media Cybernetics, Rockville, Md). The images
were analyzedusing Image-Pro Plus image-analysis software (MediaCyber-
netics). The number of immunolabeled-positive cells and the total number of
cells were counted. The results are expressed as the percentage of total cell
number per high power field. Quantification analysis was performed by
a researcher who was unaware of the treatment group.
Flow Cytometry
Before treatment and at 24 hours, 1 week, and 6 weeks after SWT, pe-
ripheral blood samples from the tail vein were obtained. Lysing buffer was
added (Pharm Lyse, BD Biosciences, Franklin Lakes, NJ) and incubated
with monoclonal mouse IgG to CD31 (eBioscience, San Diego, Calif)ery c October 2013




Sand polyclonal goat IgG to CD34 (R&DSystems,Minneapolis, Minn). The
cells were analyzed using flow cytometry with a FACSCalibur cell analyzer
(BD Biosciences). The data were further processed using BD Cell Quest
software (BD Biosciences). The results are expressed as the percentage
of the total cell number.
Blood Flow Measurement
Blood flow measurements were performed using a laser Doppler perfu-
sion image analyzer (moorLDLS, Moor Instruments, Devon, UK), as pre-
viously reported.7 To minimize the data variables attributable to ambient
light and temperature, the rats were kept on a heating plate at 37C before
measurement, and blood perfusion was expressed as the laser Doppler per-
fusion image index representing the ratio of right (operated, ischemic leg)
versus left (not operated, nonischemic leg) limb blood flow. A ratio of 1
before surgery indicated equal blood perfusion in both legs.
Walking Analysis
The CatWalk gait analysis (Noldus CatWalk XT 8.0, Wageningen, The
Netherlands) was performed, as previously reported.8 In brief, the rats
crossed a horizontal glass runway equipped with a standard charge-
coupled device camera connected to a personal computer with the CatWalk
software. The rats were tested before SWT and 1 and 6 weeks after SWT.
Every rat had to cross the walkway without any interruption or hitch. For
each rat, a minimum of 3 correct crossings was required.9
Statistical Analysis
All results are expressed as the mean standard error of the mean. Sta-
tistical comparisons between the 2 groups were performed using Student’s t
test. Continuous variables were either compared using analysis of variance
(Bonferroni) after testing for normality of the distribution or the Mann-
Whitney U test.
RESULTS
Increase of Circulating EPCs in Peripheral Blood
Flow cytometry of the peripheral blood showed no differ-
ence in the circulatingCD31-orCD34-positive cells between
groups before treatment (percentage of total cell number,
SWT, 5.03%  0.43%; CTR, 5.11%  0.42%; sham,
5.50% 0.57%). After 24 hours, significantly greater num-
bers were found in the SWT group than in the untreated con-
trols (SWT, 10.61  0.86 vs CTR, 5.4  0.42, P ¼ .005;
sham, 4.59  0.38). At 1 week after treatment, the number
of circulating progenitor cells was still elevated in the treat-
ment group (SWT, 8.32  1.73 vs CTR, 5.15  0.54,
P¼ .16; sham, 4.47 0.66). However, after 6 weeks, no dif-
ference between the treatment and control rats was observed
(SWT, 3.78  0.63 vs CTR, 2.53  0.73, P ¼ .11; sham,
4.49  0.91; Figure 1). The elevation of circulating EPCs
during the study period indicated an early mobilization of
EPCsbySWT,peakingafter 24hours.After1week, anonsig-
nificant elevation was still observed.
Increase of Angiogenic and Chemoattractive Factors
in Treated Muscle
HIF-1a plays a crucial role in the regulation of SDF-1.
SDF-1 itself serves as 1 of the most potent chemoattractants
for recruitment of EPCs from bone marrow.10 Significantly
increased mRNA levels (expressed in arbitrary units)The Journal of Thoracic and Caof HIF-1a (24 hours, SWT, 114.11  25.15 vs CTR,
39.98  1.36, P ¼ .047; sham, 91.67  6.08; 6 weeks,
SWT, 103.99  7.60 vs CTR, 69.10  5.44, P ¼ .005;
sham, 105.48  29.37) and SDF-1 (24 hours, SWT,
140  17.98 vs CTR, 47.46  10.32, P ¼ .03; sham,
144.46  48.71; 6 weeks, SWT, 111.44  13.15 vs CTR,
61.17  9.12, P ¼ .02; sham 74.00  12.49) were found in
treated muscles compared with the untreated controls
(Figure 2, A and B). At the same time, the SDF-1 receptor
C-X-C chemokine receptor type 4 was upregulated signifi-
cantly (24 hours, SWT, 709  78.75 vs CTR,
220.88  53.24, P ¼ .01; sham, 97.91  10.06; 6 weeks,
SWT, 40.67  2.13 vs CTR, 27.53  6.05, P ¼ .03; sham,
45.95  13.79; Figure 2, C). VEGF-A was upregulated in
the treatment and control group 24 hours after SWT (SWT,
297.32  60.89 vs CTR, 313.99  51.64, P ¼ .45; sham,
126.17  24.90 vs CTR, P ¼ .06; sham vs SWT, P ¼ .17).
However, in the treatment group, VEGF was still elevated
6 weeks after treatment (SWT, 216.51  37.38 vs CTR,
128.17  13.54, P ¼ .0497; sham, 159.39  23.30;
Figure 2, D). The VEGF protein concentration (given as pg/
mgprotein) confirmed this finding, with a significant increase
in the treatment group compared with the untreated controls
(SWT, 167.50  0.71 vs CTR, 124.33  16.07, P ¼ .037;
Figure 2, E). VEGF is well known, not only as the pivotal an-
giogenic growth factor, but also for its major chemoattractive
effect toward EPCs.11,12 No significant differences within the
sham groups at 24 hours and 6 weeks of follow-up were
observed in any of the analyses.
Increase of Capillary Density in Treated Ischemic
Muscles
Immunohistochemical staining forCD31-positive cells re-
vealed significantly greater numbers of capillaries at 24
hours (SWT, 51.86  4.86 vs CTR 25.15  6.66,
P ¼ .009; sham, 41.58  6.61) and 6 weeks (SWT,
66.48  4.67 vs CTR, 43.82  5.47, P ¼ .02; sham,
39.25  7.34) after SWT (Figure 3, A and C). The data are
expressed as the percentage of total cells per highpowerfield.
Significantly greater numbers of proliferating cells, prob-
ably representing endothelial cells from histologic localiza-
tion, were found in the treatment group, as shown by PCNA
staining (24hours, SWT, 43.15 5.88vsCTR, 24.59 2.62,
P¼ .0007; sham, 23.03 2.47; 6 weeks, SWT, 41.41 2.62
vsCTR, 31.10 2.62,P¼ .02; sham, 26.74 2.62; Figure 3,
B andC). Because no double-stainingwas performed (PCNA
and CD31), a part of these cells might also have represented
other cell types. These data indicate that in addition to mobi-
lization of EPCs, SWTalso stimulates local angiogenesis in
the ischemic muscle.
Restoration of Blood Perfusion
Blood perfusion of the hind limbs was measured using
laser Doppler perfusion imaging 6 weeks after treatmentrdiovascular Surgery c Volume 146, Number 4 973
FIGURE 1. Circulating CD31/CD34-positive endothelial cells. A, Fluorescence activated cell sorting (FACS) analysis of peripheral blood revealed signif-
icantly greater numbers of circulating CD31/CD34-positive endothelial cells 24 hours after shock wave treatment (SWT), indicating early mobilization of
endothelial progenitor cell, most probably from bone marrow. Number of endothelial progenitor cells still elevated after 1 week; however, 6 weeks after
SWT, no difference found between treatment and control (CTR) group. *P<.05. B, Representative views from fluorescence activated cell sorting 24 hours
after SWT showing greater numbers of endothelial progenitor cells in treatment group. FITC, Fluorescein isothiocyanate.




S(Figure 4, A-C). Significant improvement was observed in
the treatment group (SWT, 1.06  0.02 vs CTR,
0.81  0.04, P ¼ .003; sham 1.01  0.07). Data are ex-
pressed as the ratio of the left (operated, ischemic) to right
(control, nonischemic) leg (Figure 4, D).
Functional Recovery of Ischemic Limbs
Functional assessment was performed using catwalk gait
analysis 6 weeks after treatment. The functional assessment
showed that restored blood perfusion resulted in recovery of
the walking pattern in the SWT rats. Significant improve-
ment was found in the swing speed of the hind limbs
(SWT, 961.66  36.64 mm/s vs CTR, 749  41.47 mm/s,
P ¼ .002; sham, 859.19  98.1 mm/s) and in their maxi-
mum print intensity (arbitrary units; SWT, 218.02  3.58
vs CTR, 202.29  8.84, P ¼ .047; sham, 216.36  2.84;
Figure 5, A and B). Moreover, recovery was seen in the
mean stride length (SWT, 148.36  1.97 mm vs CTR,
96.44  15.22 mm, P ¼ .02; sham, 114.59  13.09 mm)
and mean print area (SWT, 131.33  26.83 mm2 vs CTR,
82.33  16.36 mm2, P ¼ .045; sham, 249.86  82 mm2;
Figure 5, C-E). Figure 5, F shows the walking pattern of
an untreated control and that of a SWT rat, clearly depicting
the restoration in walking regularity.974 The Journal of Thoracic and Cardiovascular SurgDISCUSSION
SWTwas shown to enhance recruitment of intravenously
injected EPCs to ischemic muscle in rats.5,6 Although the
combination of EPC injection and SWT showed
promising results, SWT alone would cause less side
effects in a clinical setting than would any type of cell
therapy.
In the present study, we, therefore, hypothesized that up-
regulation of chemokines SDF-1 and VEGF after SWT
would also lead to mobilization of endogenous circulating
endothelial cells eligible for vasculogenesis.13
Thus, we created a model of chronic hind limb ischemia
in rats. SWTwas applied 3 weeks after ligation of the fem-
oral artery.
Real-time polymerase chain reaction analysis of SDF-1
showed significantly greater levels in the muscle of the
treatment group than in those of the untreated controls.
Hence, at 24 hours after treatment, fluorescence activated
cell sorting analysis of the peripheral blood revealed signif-
icantly increased numbers of circulating CD31/CD34-
positive EPCs.
In line with these findings, we found a greater density of
CD31-positive capillaries in the ischemic muscle tissue 6
weeks after treatment. Together with our findings of EPCery c October 2013
FIGURE 2. Increase of angiogenic and chemoattractive factors in treated muscle. A, Expression of hypoxia-inducible factor 1a (HIF-1a) regulating stro-
mal cell-derived factor-1 (SDF-1) significantly elevated in treatment group 24 hours and 6 weeks after shockwave therapy (SWT). In linewith these findings,
B, SDF-1 and C, its receptor C-X-C chemokine receptor type 4 (CXCR-4) also significantly upregulated. Vascular endothelial growth factor (VEGF)-A
mRNA showed increased levels at 24 hours after treatment in treatment and control (CTR) groups. D, However, levels remain elevated in treatment group
even at 6 weeks after SWT. E, VEGF protein concentration (given as pg/mg protein) showed significant increase in treatment group compared with untreated
controls. *P<.05.




Smobilization, these results indicate that SWT might induce
vasculogenesis in ischemic tissue. Nevertheless, homing of
EPCs must be demonstrated in future studies.
EPCs are known to be stored in the bonemarrow, vascular
adventitia, and/or endothelium itself and to circulate in
the peripheral blood.14-16 However, the phenotypic
characterization of EPCs is still a matter of concern.17-19
We used a typical endothelial marker (CD31) and a stem
cell marker (CD34) to evaluate the effects of SWT on the
circulating EPCs. However, future experiments are needed
to demonstrate incorporation of bone marrow-derived cells
into the vasculature of ischemic muscle after SWTand their
exact origin, which we have assumed to be the bonemarrow.
EPCs are retained in the bone marrow by SDF-1, which
serves as a ligand for their C-X-C chemokine receptor
type 4 receptor. Chronic ischemic tissue loses its ability to
express chemoattractants for progenitor cells. ApplicationThe Journal of Thoracic and Caof SWT leads to increased expression of HIF-1a, which is
in part responsible for upregulation of SDF-1 and VEGF,
which themselves are also increased by SWT in ischemic
tissue. Therefore, it could be conceivable that stimulation
of HIF-1a might be upstream of VEGF and SDF-1 eleva-
tion. This, however, needs further experimental validation.
Obviously, some of the released SDF-1 enters the systemic
circulation. Greater SDF-1 serum levels cause desensitiza-
tion of progenitor cells in bone marrow, thus, increasing
their likelihood of mobilization.20 SDF-1 released around
ischemic vessels enhances tissue-specific adhesion of mobi-
lized progenitor cells.10
Additionally, VEGF-Awas upregulated in both the treat-
ment and the control group 24 hours after SWT. However, in
the treatment group, the VEGF levels remained elevated
6 weeks after treatment. This could be confirmed by the pro-
tein level, which was shown by the VEGF enzyme-linkedrdiovascular Surgery c Volume 146, Number 4 975
FIGURE 3. Increase of capillary density in treated ischemic muscle. A, Immunohistochemical staining for CD31-positive cells revealed significantly
greater numbers of capillaries 24 hours and 6 weeks after shock wave therapy (SWT). Data presented as percentage of total cells per high power field.
B, Significantly more proliferating cells found in treatment group, as shown by proliferating cell nuclear antigen (PCNA). In addition to hypothesis of en-
dothelial progenitor recruitment for vasculogenesis, this indicates additional vessel sprouting in parallel. C, Representative views of immunohistochemical
(IHC) staining for CD31 (endothelial cells) and PCNA (proliferating cells). Magnification 3400. *P<.05. CTR, Control.




Simmunosorbent assay. VEGF is well known, not only as
a main angiogenic growth factor, but also for its major che-
moattractive effect toward EPCs, serving as an adjunct to
SDF-1.11
An interesting observationwas that 24hours after SWT, the
mRNA of HIF-1a and SDF-1 was downregulated in the con-
trol groups (ischemia) compared with the sham-operated
group. VEGF, however, was upregulated in ischemia, asFIGURE 4. Restoration of blood perfusion. Blood perfusion of hind limbs mea
perfusion of sham-operated rat; B, Representative view of perfusion in untreat
therapy (SWT) rat. Blood perfusion clearly restored in treatment group. D, Quan
leg to left (nonoperated, nonischemic) leg revealing significant improvement in
976 The Journal of Thoracic and Cardiovascular Surgexpected. SWT increased HIF-1a and SDF-1, which might
indicate that the mRNA of these factors are inhibited (eg,
by miRNAs) in ischemia and that this inhibition is blunted
by SWT. This observation might indicate a new target of
SWT and deserves additional investigation in future studies.
Significantly greater numbers of proliferating endothelial
cells were found in the treatment group, as shown by PCNA
staining. In addition to the hypothesis of endothelialsured by laser Doppler perfusion imaging 6 weeks after treatment. A, Blood
ed control (CTR); and C, representative view of perfusion of shock wave
tification of measurements expressed as ratio of right (operated, ischemic)
treatment group compared with untreated controls. *P<.05.
ery c October 2013
FIGURE 5. Functional recovery of ischemic limbs. Functional assessment performed by catwalk gait analysis 6 weeks after treatment showing restored
blood perfusion resulted in recovery of walking pattern in shock wave therapy (SWT) group. Significant improvement found in A, swing speed of hind limbs
and B, their maximum print intensity. Recovery also seen in C, mean stride length and D, mean print area. E, More physiologic footprint of treatment animal
(Right) compared with typically malfunctioning step of control (CTR) animal (Left). F, Walking regularity clearly restored 6 weeks after SWT. *P<.05.




Sprogenitor recruitment, this indicates additional induction
of local angiogenesis in the ischemic muscle after SWT.
Thus, VEGF serves as the pivotal growth factor for
angiogenesis and induces blood vessel formation after ex-
perimental myocardial infarction.21
According to our morphologic findings of revasculariza-
tion, laserDoppler perfusion imaging revealeda significantly
greater perfusion rate in the treated rats 6 weeks after treat-
ment. The walking analysis was performed to evaluate the
functional improvement of the treated limbs. At 6 weeks af-
ter SWT, the rats showed a regular walking pattern, although
hardly any improvement was found in the control group.
In previous experiments, we have shown improvement in
the left ventricular ejection fraction after SWT after myo-
cardial infarction in rats. The results of the present study
support these findings and suggest that SWT in ischemic
muscle tissue could even serve as an ‘‘endogenous cell ther-
apy,’’ although in the present study, EPC mobilization only,
and not EPC homing, was shown. A treatment strategy that
induces mobilization and homing of endogenous vessel-
forming EPCs would avoid the numerous side effects asso-
ciated with any kind of cell therapy. Moreover, shock wavesThe Journal of Thoracic and Caarewell known from their use in lithotripsy for more than 30
years to cause no severe side effects. This includes no neo-
vascularization in healthy, nonischemic tissue, such as was
shown in an earlier experiment of myocardial infarction in
rats.2
Showing the same positive effects as endothelial, progen-
itor, or stem cell treatment, SWT could, therefore, be the
superior treatment strategy. It is not only safer, but also eas-
ier to handle and much more available and, thereby, more
cost-effective.
Additional studies are underway to clarify the exact
mechanisms of cell recruitment after SWT. However, our
current findings already clearly suggest that SWT could in
future not only serve as an adjunct, but even as an alterna-
tive to stem cell therapy, in ischemic heart and limb disease.References
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